icariside I: structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 5745470 |
| CHEMBL ID | 558499 |
| SCHEMBL ID | 4215872 |
| MeSH ID | M0518891 |
| Synonym |
|---|
| baohuoside-1 |
| 3,5,7-trihydroxy-4'-methoxy-8'-prenylflavone-3-o-alpha-l-rhamnopranoxide |
| 4h-1-benzopyran-4-one, 3,5-dihydroxy-7-(beta-d-glucopyranosyloxy)-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)- |
| brn 0072036 |
| icariside i |
| CHEMBL558499 |
| 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one |
| 56725-99-6 |
| 4-18-00-03374 (beilstein handbook reference) |
| S3247 |
| AKOS016013487 |
| SCHEMBL4215872 |
| lcariside i |
| AC-34999 |
| icariside-i |
| icarisid i |
| DTXSID30205283 |
| CS-0018250 |
| 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one |
| HY-N1939 |
| mfcd01662755 |
| 3,5-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4-oxo-4h-chromen-7-yl beta-d-glucopyranoside |
| IYCPMVXIUPYNHI-WPKKLUCLSA-N |
| icariside 1 |
| icariin i |
| AS-78068 |
| icarisidei |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID428313 | Reversal of P-gp-mediated multidrug resistance in human MCF7 cells assessed as assessed as increase in intracellular adriamycin accumulation at 5 uM incubated 2 hrs before adriamycin challenge by spectrophotometry | 2009 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15 ISSN: 1464-3405 | Synthesis and antimultidrug resistance evaluation of icariin and its derivatives. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ketoconazole | dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | ||
| icaritin | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| icariin | flavonols; glycosyloxyflavone | antioxidant; bone density conservation agent; EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; phytoestrogen | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| baohuoside i | glycosyloxyflavone | anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| indole | indole; polycyclic heteroarene | Escherichia coli metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| kynurenine | aromatic ketone; non-proteinogenic alpha-amino acid; substituted aniline | human metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| nigericin | polycyclic ether | antibacterial agent; antimicrobial agent; bacterial metabolite; potassium ionophore | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| daidzein | 7-hydroxyisoflavones | antineoplastic agent; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; phytoestrogen; plant metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| icaritin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| icariin | flavonols; glycosyloxyflavone | antioxidant; bone density conservation agent; EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; phytoestrogen | 2007 | 2008 | 16.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 | |
| baohuoside i | glycosyloxyflavone | anti-inflammatory agent; antineoplastic agent; apoptosis inducer; plant metabolite | 2007 | 2022 | 11.7 | high | 0 | 0 | 0 | 2 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Liver Injury, Drug-Induced | 0 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Benign Neoplasms | 0 | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Chemical and Drug Induced Liver Injury | 0 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Disease Models, Animal | 0 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Malignant Melanoma | 0 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Melanoma | 0 | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Neoplasms | 0 | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 | |
| Sensitivity and Specificity | 0 | 2007 | 2007 | 17.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| Article | Year |
|---|---|
| Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity. Cell communication and signaling : CCS, , 02-11, Volume: 19, Issue:1 | 2021 |